Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 3/20 | 0.45 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.39 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.39 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | ANPEP | P15144 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.37 |
| ▸ | PLAU | P00749 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13305784 | 1.00 | MTNR1A (0.45) | MTNR1ASMYD3MAPTGAANPC1 | |
| Methane SCHEMBL10697109 | 0.98 | MTNR1A (0.44) | MTNR1ASMYD3MAPTGAANPC1 | |
| SCHEMBL28901934 | 0.88 | MAPT (0.43) | MTNR1ASMYD3MAPTGAANPC1 | |
| SCHEMBL19774297 | 0.78 | MTNR1A (0.47) | MTNR1ASMYD3MAPTGAANPC1 | |
| SCHEMBL2781001 | 0.78 | MAPT (0.55) | MTNR1AMAPTGAANPC1KDM4E | |
| SCHEMBL31517110 | 0.78 | MAPT (0.55) | MTNR1AMAPTGAANPC1KDM4E | |
| SCHEMBL28043088 | 0.77 | MTNR1A (0.47) | MTNR1ASMYD3MAPTGAANPC1 | |
| SCHEMBL20344534 | 0.77 | ANPEP (0.50) | MTNR1ASMYD3MAPTGAANPC1 | |
| Hydrochloric Acid SCHEMBL27277923 | 0.77 | GAA (0.53) | MTNR1AMAPTGAAANPEP | |
| SCHEMBL19088009 | 0.76 | ESR2 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117427074-A | Application of tetrahydroquinolinol as iron death inhibitor in preparation of acute kidney injury drugs | 山东第一医科大学(山东省医学科学院) | 2024-01-23 | — | — | CN | claimed |
| EP-1511704-A1 | POLYMERISATION INHIBITOR | A H Marks & Company Limited (GB) | 2005-03-09 | — | — | EP | claimed |
| WO-2003106390-A1 | POLYMERISATION INHIBITOR | A H MARKS & COMPANY LIMITED (GB) | 2003-12-24 | — | — | WO | claimed |
| US-4595683-A | Gastrointestinal disorders, antiulcer agents | WILLIAM H. RORER, INC. (US) | 1986-06-17 | — | — | US | claimed |
| CN-119546588-A | Pyridine checkpoint kinase 1 (CHK 1) inhibitors and uses thereof | 无界生物公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-118488945-A | Sulfonamide ribonucleotide reductase (RNR) inhibitors and uses thereof | 无界生物公司 | 2024-08-13 | — | — | CN | disclosed |
| CN-118434417-A | Cyclic sulfonamide ribonucleotide reductase (RNR) inhibitors and uses thereof | 无界生物公司 | 2024-08-02 | — | — | CN | disclosed |
| CN-117427074-A | Application of tetrahydroquinolinol as iron death inhibitor in preparation of acute kidney injury drugs | 山东第一医科大学(山东省医学科学院) | 2024-01-23 | — | — | CN | disclosed |
| CN-117427074-A | Application of tetrahydroquinolinol as iron death inhibitor in preparation of acute kidney injury drugs | 山东第一医科大学(山东省医学科学院) | 2024-01-23 | — | — | CN | disclosed |
| CN-117427074-A | Application of tetrahydroquinolinol as iron death inhibitor in preparation of acute kidney injury drugs | 山东第一医科大学(山东省医学科学院) | 2024-01-23 | — | — | CN | disclosed |
| CN-116507626-A | Compositions and methods for modulating short-chain dehydrogenase activity | 罗迪奥治疗公司 | 2023-07-28 | — | — | CN | disclosed |
| US-11524959-B1 | Indole and azaindole inhibitors of pad enzymes | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-12-13 | — | — | US | disclosed |
| US-5410053-A | A pyrano-diquinoline addition or condensation anionic polymer as the novel xanthene dyes for dyeing polyacrylonitrile fibers ; colorfastness | BASF AKTIENGESELLSCHAFT (DE) | 1995-04-25 | — | — | US | disclosed |
| US-5324347-A | 2,6-bis hydroxyalkylamino methyl phenol; corrosion resistance, adhesion promoting | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1994-06-28 | — | — | US | disclosed |
| US-5310914-A | Imination, reduction | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1994-05-10 | — | — | US | disclosed |
| EP-0573762-A2 | Rhodamine derivatives | BASF Aktiengesellschaft (DE) | 1993-12-15 | — | — | EP | disclosed |
| US-5216164-A | Used for relieving memory dysfunction such as Alzheimer's disease | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1993-06-01 | — | — | US | disclosed |
| EP-0517356-A2 | Composition and method for inhibiting corrosion and/or promoting adhesion of a metal surface | ZENECA LIMITED (GB) | 1992-12-09 | — | — | EP | disclosed |
| EP-0489379-A1 | 5-amino-5,6,7,8-tetrahydroquinolines and related compounds, a process for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1992-06-10 | — | — | EP | disclosed |
| US-5110815-A | Alzheimer's disease | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1992-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11524959-B1 | Indole and azaindole inhibitors of pad enzymes | PADI4, PADI1, PADI2 | MTNR1A 1208/4885SMYD3 364/4885MAPT 4354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.